We are working on the mechanism and treatment strategies of age-related macular degeneration, a prevalent condition causing severe vision loss in older individuals. Particularly, we're developing new treatments to tackle the issue of drug resistance to the current treatment of corneal neovascularization, which is the wet type of AMD. Our lab recently developed new treatment to ameliorate anti-VEGF resistance in CNV.
This is achieved by using mouse CNV model. Our research has shown that old mice with laser-induced CNV develop arteriolar CNV, which is resistant to anti-VEGF treatment. In contrast, young mice with capillary CNV are responsive to the treatment.
In AMD research, CNV is almost exclusively studied by fluorescein angiography to reveal leakage patterns in animal models. However, FA does not show CNV vascular morphology, and thus it is not suitable to study anti-VEGF resistance in AMD. The current FA method used for CNV imaging lacks vital information regarding the vascular morphology of CNV lesions, such as capillary or arteriolar CNV.
However, by combining ICGA and FA, this protocol can evaluate both CNV leakage and vascular morphology. By assessing both leakage and CNV lesion morphology, it is possible to study the underlying molecule mechanism relating to arteriolar CNV, and therefore provide opportunities to find new targets to treat anti-VEGF resistance for AMD patients.
